methylphenidate tablet / Generic mfg. - LARVOL DELTA

Preliminary exploration of the role and mechanism of BAIAP2 in learning and memory impairment in ADHD. (PubMed, Physiol Behav) - "Notably, methylphenidate (MPH) treatment increased BAIAP2 levels, while targeted BAIAP2 overexpression rescued learning and memory deficits, as evidenced by Morris water maze (MWZ) performance. Furthermore, we preliminarily explored the possible regulatory interactions between BAIAP2 and the long non-coding RNA lncNONRATT002035.2. These findings establish BAIAP2 as a pivotal mediator of hippocampal-dependent learning and memory dysfunction in ADHD and uncovered new aspects of disease pathology and potential targets for therapy.The newly discovered lncNONRATT002035.2-BAIAP2 axis warrants further investigation to elucidate its pathophysiological significance."

Journal • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry • BAIAP2

Tatton-Brown-Rahman Syndrome Due to a Novel DNMT3A Variant Presenting With Autism, Attention-Deficit/Hyperactivity Disorder (ADHD), and Regression: A Saudi Case Report. (PubMed, Cureus) - "He was diagnosed with ASD and attention-deficit/hyperactivity disorder (ADHD) and treated with methylphenidate in childhood...This case emphasizes the importance of multidisciplinary evaluation and lifelong neuropsychiatric follow-up in TBRS. As the first reported case from Saudi Arabia to our knowledge, it broadens the clinical and geographic spectrum of the disorder and highlights the association between DNMT3A variants, intellectual disability, and ASD."

Journal • ADHD (Impulsive Aggression) • Atopic Dermatitis • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Dermatology • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Immunology • Mental Retardation • Psychiatry • DNMT3A

Targeting central immune signaling enhances the effects of methylphenidate in alleviating apathy-like behavior in 5xFAD mice. (PubMed, Res Sq) - "Combined SB290157 and methylphenidate treatment significantly improved nest-building behavior, reduced C3 and C3ar protein expression, as well as restored dendritic spine density in the PFC. Our results confirm complement-mediated immune dysregulation is linked to apathy and suggest that co-targeting complement and catecholaminergic pathways may offer a novel therapeutic strategy for alleviating apathy in AD."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Psychiatry • C1QA • C1QB • TYROBP

Methylphenidate, Sleep, and the "Stimulant Paradox" in Adult ADHD: A Conceptual Framework for Integrating Chronopharmacotherapy and Coaching. (PubMed, J Clin Med) - "The review identifies critical areas for future research, emphasizing the need for empirical investigation into optimal clock-time windows, phase measures, and chronotype stratification. Additionally, assumptions regarding medication formulations warrant further scrutiny to refine timing-sensitive interventions in adult ADHD management."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

The efficacy and safety of antidepressants as alternative treatment of attention-deficit/hyperactivity disorder in pediatric populations. (PubMed, Ment Health Clin) - "Beyond behavioral therapy approaches, methylphenidate and amphetamine stimulant agents are recommended as first-line pharmaceutical treatments for ADHD...Particular focus on selective serotonin reuptake inhibitors, SNRIs, tricyclic antidepressants, and bupropion was demonstrated in the literature. More research needs to be conducted to fully explore the effects and efficacy of antidepressants compared with first-line medications for ADHD. In addition, data supporting long-term effects and efficacy for antidepressants in ADHD are not yet established."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Pediatrics • Psychiatry

Is the ADHD bomb about to explode? The impact of the medicalization of attention-deficit/hyperactivity disorder on its pharmacotherapy and institutional context in Hungary (PubMed, Orv Hetil) - "It provides a detailed discussion of the benefits and risks of methylphenidate, the issue of misuse, and the role of atomoxetine as an alternative. Orv Hetil. 2025; 166(49): 1935-1942."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Amphetamine in adolescence induces a sex-specific mesolimbic dopamine phenotype in the adult prefrontal cortex. (PubMed, Commun Biol) - "However, only in males, amphetamine increases PFC dopamine transporter expression in adulthood (PND 101 ± 15): leading to aberrant baseline dopamine transients, faster dopamine release, and exaggerated responses to acute methylphenidate. Upregulation of DCC in adolescence, using CRISPRa, prevents all these changes. Mesolimbic dopamine axons rerouted to the PFC in adolescence retain anatomical and functional phenotypes of their intended target, rendering males enduringly vulnerable to the harmful effects of drugs of abuse."

Journal • Psychiatry • NTN1

The ADME profile of Threo-4-methylmethylphenidate (4-Mmph, 4-MeTMP, CAS: 467468-40-2) as New Psychoactive Substance (NPS): prediction of absorption, distribution, metabolism and excretion parameters using integrated in silico approach for clinical and forensic purposes. (PubMed, Chem Biol Interact) - "Potential phase I and phase II reactions are also indicated within this study. 4-Mmph is not identified as a substrate for the renal organic cation transporter OCT2, implying alternative renal excretion pathways."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry • CYP2C19 • CYP2C9 • CYP3A4

Does the Use of Methylphenidate Affect Bone Health? A Systematic Review and Meta-analysis of Preclinical Studies. (PubMed, Calcif Tissue Int) - "The findings emphasize the need for further research into the mechanisms behind MP's impact on bone, including age at MP treatment initiation and treatment duration, dose-response relationships, and sex differences. Better understanding of the metabolic pathways which influence MP's effects on the above endpoints could clarify broader implications of MP use on skeletal health and inform clinical practices."

Clinical • Journal • Preclinical • Retrospective data • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Musculoskeletal Diseases • Orthopedics • Psychiatry

Time Course of Serum Dextromethorphan Concentrations in a Case of Serotonin Syndrome After Massive Overdose. (PubMed, Am J Case Rep) - "CASE REPORT A 24-year-old man with bipolar disorder and attention-deficit/hyperactivity disorder, treated with trazodone and methylphenidate, ingested 300 mg of DXM (4.6 mg/kg)...He developed serotonin syndrome with spontaneous clonus and seizures, requiring diazepam, sedation, intubation, and ventilation...CONCLUSIONS Our case report provides a detailed timeline of blood DXM concentrations along with the clinical course in a patient with serotonin syndrome after an acute overdose. The serial measurements support the importance of symptom-focused monitoring to guide treatment decisions."

Journal • ADHD (Impulsive Aggression) • Anesthesia • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Epilepsy • Mood Disorders • Psychiatry

Neuroprotective Effects of Yizhi Decoction via Inhibition of PINK1/Parkin-Mediated Mitophagy in the Prefrontal Cortex of Rats with Attention Deficit Hyperactivity Disorder. (PubMed, J Ethnopharmacol) - "YZD alleviates neuronal oxidative stress and damage in ADHD rat models by limiting excessive PINK1/Parkin-mediated mitophagy."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry • BECN1 • PINK1 • PTEN

Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). (PubMed, Cochrane Database Syst Rev) - "The majority of our conclusions from the 2015 version of this review still apply. Our updated meta-analyses suggest that methylphenidate versus placebo or no-intervention may improve teacher-rated ADHD symptoms and general behaviour in children and adolescents with ADHD. There may be no effects on serious adverse events and quality of life. Methylphenidate may be associated with an increased risk of adverse events considered non-serious, such as sleep problems and decreased appetite. However, the certainty of the evidence for all outcomes is very low and therefore the true magnitude of effects remain unclear. Due to the frequency of non-serious adverse events associated with methylphenidate, the blinding of participants and outcome assessors is particularly challenging. To accommodate this challenge, an active placebo should be sought and utilised. It may be difficult to find such a drug, but identifying a substance that could mimic the easily recognised adverse effects..."

Clinical • Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mental Retardation • Psychiatry • Sleep Disorder

Developmental deviations of structural connectivity in youths with ADHD predict symptom and treatment outcomes. (PubMed, bioRxiv) - "Baseline deviations also predicted 12-week treatment response to atomoxetine, but not methylphenidate, and follow-up imaging revealed treatment-related reductions in deviation. Together, these findings identify SC deviation as a robust developmental biomarker with prognostic and theragnostic relevance for ADHD, supporting precision care through risk stratification, individualized pharmacotherapy selection, and objective monitoring of treatment effects."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Methamphetamine modulates functional connectivity signatures of sustained attention and arousal. (PubMed, Biol Psychiatry Cogn Neurosci Neuroimaging) - "Together, these findings align with prior work on other psychostimulants like methylphenidate, showing that MA modulates sustained attention and related large-scale brain networks. By revealing how MA modulates attention-relevant brain connectivity patterns, our results highlight the utility of psychostimulants as causal tools for probing the robustness, generalizability, and interpretability of brain-based biomarkers of behavior."

Journal

Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. (PubMed, BMJ) - "This review provides updated evidence to inform patients, practitioners, and guideline developers how best to manage ADHD symptoms. The online platform should facilitate the implementation of shared decision making in daily practice."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Practice Guideline for Methylphenidate Use in Persons with Traumatic Brain Injury: Report of the American Congress of Rehabilitation Medicine. (PubMed, Arch Phys Med Rehabil) - "While MPH is usually well tolerated among adults with TBI, clinicians should follow standard assessment, education, dosing, and monitoring recommendations when prescribing MPH to optimize its safety and tolerability. A summary of all recommendations on the use of MPH in TBI is available at the end of the CPG."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Psychiatry • Vascular Neurology

ADHD Medications and Preadolescent Brain Structure: Patterns of Cortical Attenuation from the ABCD Study. (PubMed, bioRxiv) - "Stimulants-including amphetamine-based (AMP) and methylphenidate-based (MPH) medications-act primarily on dopaminergic and noradrenergic systems, while nonstimulants (NS) more selectively target noradrenergic pathways. NS medications showed a similar, albeit weaker, effect pattern. Notably, AMP and/or MPH use was associated with significant effects in the right entorhinal cortex and the right banks of the superior temporal sulcus, potentially reflecting overcompensatory effects, as well as in the left posterior cingulate, possibly indicating de novo medication-related differences."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

Methylphenidate for Depression in Advanced Cancer:Exploratory Meta-Analysis of Randomized Trials. (PubMed, J Pain Symptom Manage) - "MPH may provide rapid, potentially meaningful improvement in depressive symptoms for people living with advanced cancer, while maintaining a favorable safety profile. Considering the small sample sizes and short follow-up durations across studies included in this exploratory meta-analysis, future large-scale trials are needed to confirm efficacy and define optimal candidates."

Journal • Retrospective data • CNS Disorders • Depression • Mood Disorders • Oncology • Psychiatry

Longitudinal study on the seasonal variation in methylphenidate consumption in the South African private healthcare sector. (PubMed, Explor Res Clin Soc Pharm) - "There was a clear visible upward trend in the consumption of methylphenidate, with a decrease during 2020, as was also observed in other countries. Similar studies are recommended for other central nervous system drug classes."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Psychiatry • Respiratory Diseases

Systematic Review on Norepinephrine and Dopamine Reuptake Inhibitors for Traumatic Brain Injury-Related Symptoms: Report of the American Congress of Rehabilitation Medicine. (PubMed, Arch Phys Med Rehabil) - "Among adults with TBI, MPH has medium effects on selective attention, sustained attention, and processing speed, and large effects on depressive symptoms. These effects are consistent with MPH's biological mechanisms and are not moderated by injury severity or time since injury."

Journal • Review • CNS Disorders • Cognitive Disorders • Depression • Psychiatry • Vascular Neurology

Methylphenidate stabilizes dynamic brain network organization during tasks probing attention and reward processing in stimulant-naïve children with ADHD. (PubMed, Transl Psychiatry) - "Further, individuals with greater decreases in whole brain flexibility on MPH exhibited greater improvements in task performance. Together, these results provide novel insights into the neurobiological mechanisms underlying the effectiveness of MPH administration for children with ADHD."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

The incidence, prevalence and treatment of narcolepsy in New Zealand. (PubMed, N Z Med J) - "This is the first national estimate of the incidence and prevalence of narcolepsy in New Zealand. The mismatch between diagnosis and treatment data likely reflects limited diagnostic access, multiple medication use, the existence of imported cases with established diagnoses and the treatment of idiopathic hypersomnolence (IH) under the guise of narcolepsy. Policy and funding changes are needed to improve care access and reporting accuracy."

Journal • Narcolepsy • Sleep Disorder

Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans (clinicaltrials.gov) - P1 | N=122 | Completed | Sponsor: University of Zurich | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Apr 2025 ➔ Sep 2025

Trial completion • Trial completion date • Trial primary completion date

Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm. (PubMed, J Addict Med) - "Our results suggest that the ECG sensors' discriminatory power is based on nuances in ECG data beyond mere changes in heart rate."

Journal • Tobacco Addiction

Methylphenidate in Childhood Apraxia of Speech (clinicaltrials.gov) - P2 | N=18 | Completed | Sponsor: Murdoch Childrens Research Institute | Active, not recruiting ➔ Completed

Trial completion